Authors: – Shweta Khandibharad (Senior Scientific Specialist I , Bioinformatics )
In brief: multi-omics AI in precision medicine integrates epigenetics, genomic mutations, transcriptomic expression, proteomics signaling, metabolomic profiles, and longitudinal clinical records using AI models — including transformer architectures and graph neural networks — to predict individual patient treatment response with 0.81–0.87 AUC accuracy in oncology, accelerate clinical trial enrollment by 42%, and enable adaptive therapy models that adjust treatment before clinical deterioration occurs.
Introduction
Precision medicine is entering a new era. As diseases are recognized as increasingly complex and biologically diverse, traditional one-size-fits-all treatment approaches are giving way to more individualized strategies. The focus is shifting from treating symptoms to understanding the molecular mechanisms that make every patient unique.
At the center of this transformation is the convergence of artificial intelligence, multi-omics research, and clinical data science. Together, these advances are enabling researchers to uncover deeper biological insights, improve therapeutic decision-making, and move healthcare toward more predictive, adaptive, and personalized care.
The convergence of multi-omics analytics and AI described here builds on decades of work in bioinformatics infrastructure, data standardization, and computational biology. For a broad perspective on how the field arrived at this moment, Excelra’s blog on Empowering Drug Discovery with Big Data and Artificial Intelligence traces the evolution from early data-driven approaches to the AI-powered multi-omics integration that is now reshaping precision therapy decisions.
1. Why single biomarkers are no longer enough
Historically, precision medicine relied heavily on single-gene biomarkers such as EGFR or HER2 mutations. While these markers improved targeted therapy, they often failed to capture tissue heterogeneity and spatio-temporal disease evolution.
Current studies demonstrate that combining genomics with epigenomics, transcriptomics, proteomics and metabolomics can dramatically improve therapeutic prediction accuracy (Hsu CY et al., 2025). For example, AI-powered multi-modal oncology platforms now identify resistance pathways before clinical relapse becomes visible through imaging (Fang C et al., 2025).
To the best of our knowledge, the greatest limitation is rarely the lack of sequencing, but it is the inability to interpret complex biological interaction networks across multiple systems simultaneously.
The failure of single-biomarker approaches is well-documented in oncology — where EGFR and HER2 mutations capture only a slice of the tumour’s biological complexity. Excelra’s case study on Identification of Predictive Biomarkers and Applications in Patient Enrichment Strategies demonstrates how moving beyond single biomarkers — integrating multiple molecular signatures across patient subgroups — substantially improved the ability to identify patients most likely to respond to targeted therapy, exactly the shift from single-marker to multi-omics thinking described here.
2. Multi-Omics AI in transforming clinical Decision-Making
Now, AI models can integrate millions of biological variables into treatment-response predictions. Transformer-based architectures and graph neural networks are increasingly used to identify hidden molecular relationships in patients (Madan S et al., 2024).
Over 20 years, Multi-Omics AI transformed personalized therapy. Precision oncology now achieves 0.81–0.87 AUC detection accuracy, 42% faster trial enrollment, and oncology multi-omics markets growing at 15–18% CAGR, projected from ~$1.1B (2024) to ~$4.9B by 2033.
A major breakthrough between 2020–2026 has been the use of foundation models trained on genomic and clinical datasets (Feng H et al., 2025). These systems can stratify patients into highly specific therapeutic subgroups, enabling clinicians to optimize drug selection at earliest in treatment regime.
This is particularly transformative in oncology, rare diseases, and immunotherapy response prediction, where biological variability directly influences survival outcomes.
The patient stratification capability described here — using AI to classify patients into molecularly defined subgroups for therapy optimization — is directly supported by high-quality, structured biomarker data. Excelra’s GOBIOM platform is the world’s largest repository of clinical, pre-clinical, and exploratory biomarkers and provides exactly the kind of curated, multi-omics biomarker intelligence that foundation models and clinical decision support systems require as training and inference inputs. See GOBIOM’s Biomarker Database for Enabling Precision Medicine for an overview of how GOBIOM powers precision medicine data needs.
3. The future is predictive and adaptive therapy
The next phase of precision medicine will move beyond static treatment decisions. Multi-omics AI will increasingly support adaptive therapy models where treatment evolves continuously based on patient’s profile monitoring.
Liquid biopsy, wearable biosensors, and longitudinal AI analytics are enabling real-time disease tracking (Kumar A et al., 2025). This means, therapy could eventually be adjusted before clinical deterioration in patient occurs.
Organizations investing in interoperable biological data ecosystems today, will define the future of personalized healthcare tomorrow.
The interoperable biological data ecosystem described here depends on more than technology — it requires standardized, analysis-ready datasets that can flow between clinical systems, AI models, and decision-support tools without manual intervention. Excelra’s case study on Structured and Analysis-Ready Data for AI/ML-Based Drug Discovery demonstrates what this infrastructure looks like in practice — showing how curated, AI-ready multi-omics datasets enable the real-time adaptive analytics that liquid biopsy and wearable biosensor programmes require downstream.
Conclusion
Multi-omics AI represents more than a technological advancement; it represents a new operating system for medicine. By integrating biological complexity into clinical decision-making, healthcare is moving toward truly individualized therapy strategies.
The key takeaway is clear: the leaders in healthcare will not simply generate more data; they will build systems capable of converting biological data into actionable clinical intelligence.
For researchers, clinicians, and biotech innovators, the actionable priority is to work towards data integration capabilities. The next era of personalized therapy will belong to researchers that can transform DNA into decisions.
Multi-omics driven personalized treatment in patients with different modalities.
Multi-omics AI in precision medicine, as described in this article, is the integration of epigenomics, genomic mutations, transcriptomics, proteomics, metabolomics, and longitudinal clinical data using AI architectures — including transformers and graph neural networks — to predict individual patient treatment response, stratify patients into molecularly defined therapeutic subgroups, and enable adaptive therapy models that adjust treatment in real time before clinical deterioration occurs. As this article concludes: the leaders in healthcare will not simply generate more data — they will build systems capable of converting biological data into actionable clinical intelligence.
Excelra combines multi-omics data infrastructure, AI-driven analytics, and biomarker intelligence to help pharmaceutical, biotech, and clinical research organizations move from data generation to precision therapy decisions. To explore how Excelra’s capabilities support precision medicine programmes, visit our Bioinformatics services.
Fig. 1. Multi-omics driven personalized treatment in patients with different modalities.
References
- Hsu CY, et al. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clin Exp Med. 2025;26(1):29. https://doi.org/10.1007/s10238-025-01965-9
- Fang C, et al. Artificial intelligence in oncology drug development and management: a precision medicine perspective. Front Oncol. 2025;15:1609827. https://doi.org/10.3389/fonc.2025.1609827
- Madan S, et al. Transformer models in biomedicine. BMC Med Inform Decis Mak. 2024;24(1):214. https://doi.org/10.1186/s12911-024-02600-5
- Feng H, et al. Benchmarking DNA foundation models for genomic and genetic tasks. Nat Commun. 2025;16(1):10780. https://doi.org/10.1038/s41467-025-65823-8
- 24lifesciences.com. Precision medicine market. https://www.24lifesciences.com/precision-medicine-market-1734
- Kumar A, et al. Artificial Intelligence-Based Wearable Sensing Technologies for the Management of Cancer, Diabetes, and COVID-19. Biosensors (Basel). 2025;15(11):756. https://doi.org/10.3390/bios15110756
What is multi-omics AI in precision medicine?
Multi-omics AI in precision medicine is the integration of multiple biological data layers — including epigenomics, genomic mutations, transcriptomic expression, proteomics signaling, and metabolomic profiles — combined with longitudinal clinical records, using artificial intelligence models to predict how individual patients will respond to therapy. Unlike single-biomarker approaches that rely on one or two genetic markers, multi-omics AI processes millions of biological variables simultaneously to identify complex molecular interaction networks that single-modality analysis cannot capture. Transformer-based architectures and graph neural networks are the primary AI approaches used to reveal hidden molecular relationships across these data layers. In clinical practice, multi-omics AI enables patient stratification into molecularly defined therapeutic subgroups, identification of resistance pathways before clinical relapse becomes visible through imaging, and adaptive therapy models that adjust treatment in real time — moving medicine from reactive to predictive and personalized.
Why are single biomarkers like EGFR and HER2 no longer sufficient for precision medicine?
Single-biomarker approaches like EGFR or HER2 mutation testing were landmark advances in targeted therapy, but they consistently fail to capture the full biological complexity that determines whether a patient responds to treatment. The primary limitation is that human diseases — particularly cancer — are characterized by tissue heterogeneity and spatio-temporal evolution: the same tumour contains genetically distinct cell populations, and these populations change over time in response to therapy. A single genomic marker captures one dimension of this complexity at one point in time. Clinical trials and real-world evidence now demonstrate that combining genomics with epigenomics, transcriptomics, proteomics, and metabolomics dramatically improves therapeutic prediction accuracy. AI-powered multi-modal oncology platforms can identify molecular resistance pathways before clinical relapse becomes detectable through imaging — a capability that single-biomarker analysis cannot approach. The shift from single markers to multi-omics AI is not incremental but represents a fundamental change in the resolution of precision medicine.
What performance metrics has AI-driven precision oncology achieved?
AI-driven precision oncology has achieved measurable performance milestones that quantify its clinical impact. In detection and treatment response prediction, multi-omics AI platforms now achieve 0.81–0.87 AUC (area under the receiver operating characteristic curve), representing high discriminative accuracy for classifying patients by likely therapeutic response. In clinical operations, AI integration has been associated with 42% faster clinical trial enrollment by enabling more precise patient stratification and eligibility identification. In market terms, the oncology multi-omics market is growing at 15–18% compound annual growth rate, projected to expand from approximately $1.1 billion in 2024 to approximately $4.9 billion by 2033. These figures reflect the convergence of technical capability and commercial adoption: multi-omics AI is no longer a research-stage concept but an increasingly deployed clinical decision-support infrastructure with measurable operational and financial consequences for healthcare organizations that adopt or delay adoption.
What are foundation models in genomics and how are they used in personalized therapy?
Foundation models in genomics are large AI models pre-trained on massive genomic and clinical datasets — analogous to large language models in text, but trained on DNA sequences, gene expression profiles, and associated clinical outcomes. A major breakthrough between 2020 and 2026 has been the development of these systems, which can be fine-tuned for specific clinical tasks: patient stratification into therapeutic subgroups, treatment response prediction, variant effect prediction, and biomarker discovery. Because they are pre-trained on broad biological patterns before being adapted to specific clinical questions, foundation models can achieve high performance even in disease areas with limited labeled training data — making them particularly valuable in rare diseases and emerging therapeutic modalities like T-cell engagers and ADCs. The ICH M15 guideline and FDA’s evolving AI regulatory framework are both relevant to how foundation model outputs are documented and submitted as evidence in drug development programs.
How will liquid biopsy and wearable biosensors enable adaptive precision therapy?
Liquid biopsy — the analysis of cell-free DNA, circulating tumor cells, exosomes, and other molecular markers from blood samples — and wearable biosensors that continuously monitor physiological parameters are together enabling real-time molecular monitoring of disease progression and treatment response. In precision medicine, their significance is the shift from static to dynamic therapy: rather than making treatment decisions based on a biopsy taken before therapy begins and then waiting for imaging to show whether it is working, liquid biopsy provides longitudinal molecular signals that can detect early resistance mechanisms or therapy response weeks to months before clinical indicators change. Wearable biosensors add physiological context — metabolic state, inflammatory markers, activity patterns — that complements molecular monitoring. Combined with longitudinal AI analytics that can interpret these continuous data streams, the result is an adaptive therapy model where treatment protocols can be adjusted before clinical deterioration occurs, rather than reactively after it has.
What does interoperable biological data ecosystem mean for personalized healthcare?
An interoperable biological data ecosystem in the context of personalized healthcare is a connected infrastructure in which diverse biological and clinical data sources — genomic databases, electronic health records, clinical trial datasets, real-world evidence repositories, multi-omics biobank data, and continuous monitoring streams from liquid biopsy and wearable devices — can exchange, integrate, and be queried as a unified data environment without manual format conversion or siloed access constraints. Interoperability matters because the multi-omics AI systems that drive precision medicine are only as useful as their data inputs: a treatment response model that cannot access a patient’s historical genomic data, current transcriptomic profile, and recent liquid biopsy results simultaneously cannot make a well-informed prediction. Organizations that invest in building interoperable biological data ecosystems today will be able to deploy adaptive AI therapy models that continuously learn from new patient data, while organizations that maintain fragmented data silos will be limited to increasingly outdated static predictions.
Ready to Build Precision Medicine Data Capabilities?
Excelra provides multi-omics data integration, AI-driven biomarker analytics, and clinical decision support capabilities that help pharmaceutical, biotech, and clinical research organizations move from fragmented molecular data to actionable precision therapy decisions. Whether you are building patient stratification pipelines, curating multi-omics training datasets for AI, or designing interoperable biological data ecosystems, our team is ready to collaborate.
